Swedish Orphan Biovitrum Ltd (Sobi™), the Cambridge-based UK affiliate of the international specialty healthcare company Sobi AB, today announces that it has been rated in first place among companies supplying haemophilia treatments as judged by the IPC Associates’ annual survey 2016 of this market.
Sobi™ rated as the UK’s top haemophilia company for 2016
As a relative newcomer to the haemophilia area, Sobi has been labelled a ‘transparent and trustworthy company’, with patient support groups welcoming its ‘honest and positive’ attitude.
Scoring between ‘very good’ and ‘outstanding’ in 70% of activities, Sobi is delighted to have made such a significant impact in its first full year of commercial haemophilia operations the UK, building on its existing rare disease experience and applying this within haemophilia. In five of the eight categories Sobi heads all organisations in the field.
IPC Associates’ independent annual survey has been operating for over 20 years and compares UK companies who supply fully licensed coagulation products or products on clinical trial or under marketing/clinical investigation. In 2016, twelve suppliers of products to the Haemostasis market were included. IPC Associates conduct the survey via personal and confidential interviews with healthcare professionals working in haemophilia treatment centres as well as people working for patient support groups.
Described as an ‘exciting company with exciting products’, Sobi received very positive feedback for its ‘sales and marketing’ and ‘sales service support’ activities, with respondents commenting on Sobi’s high levels of skill, technical knowledge and positive hands-on approach.
“On behalf of the therapeutic area of haemophilia at Sobi, I welcome this survey outlining Sobi as an ethical and a trustworthy company. One of our primary strategies last year was to earn the trust of everyone involved with haemophilia in the UK via a credible scientific but practical approach to all our interactions. The results of this survey help us believe we’re doing the right thing, and will continue to do so in the future”, says Paul Cox, Sobi’s Business Unit Director Haemophilia, UK & Ireland.
Sobi also excelled in the ‘product range’ and ‘quality/safety’ categories, with a near outstanding and actual market leader rating for the ‘state of art’ category. ‘Literature’ and ‘medical/technical support’ scores are already well above ‘average’ for the industry for Sobi’s first year in the rankings.
Sobi’s history of innovation in haemophilia treatments stretches over 50 years. We have the simple goal to provide people with haemophilia treatment choices that will help them live the lives they want. Read more at www.sobihaemophilia.com
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients.